|
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant . . .
This randomized phase 1b 2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer
- Gilead and Arcus Announce Etrumadenant Plus . . . - Gilead Sciences
ARC-9 (NCT04660812) is a Phase 1b 2 trial evaluating the safety and efficacy of etrumadenant (E), a dual A2a A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (if not contraindicated) in three cohorts of patients with mCRC
- Clinical Trials Using Etrumadenant - NCI - National Cancer Institute
The clinical trials on this list are studying etrumadenant All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI
- Etrumadenant and Zimberelimab in Melanoma and Renal Cell Carcinoma and . . .
Eligible participants will receive oral administration of etrumadenant as well as IV infusion of zimberelimab The recommended Phase 2 dose (RP2D) of etrumadenant will be determined upon completion of the dose-escalation phase
- etrumadenant - My Cancer Genome
Etrumadenant has been investigated in 11 clinical trials, of which 10 are open and 1 is closed Of the trials investigating etrumadenant, 4 are phase 1 (3 open), 4 are phase 1 phase 2 (4 open), and 3 are phase 2 (3 open)
- Ozmosi | Etrumadenant Drug Profile
AB928, a selective, small-molecule A2aR A2bR antagonist, potently blocks the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen . . .
ARC-9 (NCT04660812) is a Phase 1b 2 trial evaluating the safety and efficacy of etrumadenant (E), a dual A2a A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (if not contraindicated) in three cohorts of patients with mCRC
- Zimberelimab and Quemliclustat and Etrumadenant in Pancreatic Ductal . . .
In Stage 2, participants will be randomized into one of three different treatment arms (B - D)
|
|
|